[{"address1": "545 Concord Avenue", "address2": "Suite 210", "city": "Cambridge", "state": "MA", "zip": "02138", "country": "United States", "phone": "857 702 9600", "website": "https://www.metaviatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc.  operates as a subsidiary of Dong-A ST Co., Ltd.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. Heon Kim  Hyung", "age": 47, "title": "CEO, President & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 716404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marshall H. Woodworth", "age": 66, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 565684, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mi-Kyung  Kim", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Homolka", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. W. Christopher Fang M.D.", "title": "Consulting Chief Medical Officer & Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Pine", "age": 48, "title": "Senior Vice President of Business Development Advisor", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9823, "open": 0.9822, "dayLow": 0.9822, "dayHigh": 1.03, "regularMarketPreviousClose": 0.9823, "regularMarketOpen": 0.9822, "regularMarketDayLow": 0.9822, "regularMarketDayHigh": 1.03, "payoutRatio": 0.0, "beta": 0.368, "volume": 122572, "regularMarketVolume": 122572, "averageVolume": 1658142, "averageVolume10days": 181720, "averageDailyVolume10Day": 181720, "bid": 0.96, "ask": 1.02, "bidSize": 7, "askSize": 11, "marketCap": 24923742, "fiftyTwoWeekLow": 0.556, "fiftyTwoWeekHigh": 3.27, "allTimeHigh": 129540.0, "allTimeLow": 0.556, "fiftyDayAverage": 0.76898, "twoHundredDayAverage": 1.13531, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 7430743, "profitMargins": 0.0, "floatShares": 7962773, "sharesOutstanding": 24197809, "sharesShort": 99727, "sharesShortPriorMonth": 145940, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.0041, "heldPercentInsiders": 0.62555003, "heldPercentInstitutions": 0.06358, "shortRatio": 0.02, "shortPercentOfFloat": 0.0108, "impliedSharesOutstanding": 24197809, "bookValue": 0.398, "priceToBook": 2.5879395, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -18491000, "trailingEps": -0.97, "lastSplitFactor": "1:8", "lastSplitDate": 1703116800, "enterpriseToEbitda": -0.371, "52WeekChange": -0.61851853, "SandP52WeekChange": 0.17904854, "quoteType": "EQUITY", "currentPrice": 1.03, "targetHighPrice": 21.0, "targetLowPrice": 3.0, "targetMeanPrice": 13.75, "targetMedianPrice": 15.5, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 17591000, "totalCashPerShare": 0.727, "ebitda": -20012000, "totalDebt": 98000, "quickRatio": 1.994, "currentRatio": 2.077, "debtToEquity": 1.018, "returnOnAssets": -0.53037, "returnOnEquity": -1.29462, "freeCashflow": -13114375, "operatingCashflow": -18903000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MTVA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 4.85595, "regularMarketPrice": 1.03, "shortName": "MetaVia Inc.", "longName": "MetaVia Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470403800000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.03, "postMarketChange": 0.0, "regularMarketChange": 0.0477, "regularMarketDayRange": "0.9822 - 1.03", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1658142, "fiftyTwoWeekLowChange": 0.47399998, "fiftyTwoWeekLowChangePercent": 0.85251796, "fiftyTwoWeekRange": "0.556 - 3.27", "fiftyTwoWeekHighChange": -2.24, "fiftyTwoWeekHighChangePercent": -0.6850153, "fiftyTwoWeekChangePercent": -61.851852, "dividendDate": 1577750400, "earningsTimestampStart": 1755001800, "earningsTimestampEnd": 1755520200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.97, "fiftyDayAverageChange": 0.26101995, "fiftyDayAverageChangePercent": 0.33943656, "twoHundredDayAverageChange": -0.10531008, "twoHundredDayAverageChangePercent": -0.09275887, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroBo Pharmaceuticals, Inc.", "nameChangeDate": "2025-10-02", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1759531150, "regularMarketTime": 1759521601, "exchange": "NCM", "messageBoardId": "finmb_630763379", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "displayName": "MetaVia", "trailingPegRatio": null, "__fetch_time": "2025-10-04"}]